Literature DB >> 32141023

Osilodrostat: First Approval.

Sean Duggan1.   

Abstract

Osilodrostat (Isturisa®) is an orally available small molecule 11β-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing's disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing's syndrome in adults and is under regulatory review in the USA for the treatment of Cushing's disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32141023     DOI： 10.1007/s40265-020-01277-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  5 in total

1.  Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.

Authors:  Sara G Creemers; Richard A Feelders; Frank H de Jong; Gaston J H Franssen; Yolanda B de Rijke; Peter M van Koetsveld; Leo J Hofland
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

2.  LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

Authors:  Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

3.  Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.

Authors:  Sara Armani; Lillian Ting; Nicholas Sauter; Christelle Darstein; Anadya Prakash Tripathi; Lai Wang; Bing Zhu; Helen Gu; Dung Yu Chun; Heidi J Einolf; Swarupa Kulkarni
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

4.  Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.

Authors:  Joël Ménard; Dean F Rigel; Catherine Watson; Arco Y Jeng; Fumin Fu; Michael Beil; Jing Liu; Wei Chen; Chii-Whei Hu; Jennifer Leung-Chu; Daniel LaSala; Guiqing Liang; Sam Rebello; Yiming Zhang; William P Dole
Journal:  J Transl Med       Date:  2014-12-10       Impact factor: 5.531

5.  Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.

Authors:  Maria Fleseriu; Rosario Pivonello; Jacques Young; Amir H Hamrahian; Mark E Molitch; Chikara Shimizu; Tomoaki Tanaka; Akira Shimatsu; Tracy White; Annie Hilliard; Chuan Tian; Nicholas Sauter; Beverly M K Biller; Xavier Bertagna
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107
  5 in total
  6 in total

1.  Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.

Authors:  Cédric Fontaine-Sylvestre; Laurent Létourneau-Guillon; Robert A Moumdjian; France Berthelet; André Lacroix
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

Review 2.  Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies.

Authors:  Xi Wang; Yuanxun Wang; Xuemin Li; Zhenyang Yu; Chun Song; Yunfei Du
Journal:  RSC Med Chem       Date:  2021-08-10

3.  Obstetric and Neonatal Outcome of Pregnancy in Carney Complex: A Case Report.

Authors:  Damian J Ralser; Brigitte Strizek; Patrick Kupczyk; Birgit Stoffel-Wagner; Julia Altengarten; Andreas Müller; Joachim Woelfle; Ulrich Gembruch; Dietrich Klingmueller; Waltraut M Merz; Anke Paschkowiak-Christes
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-08       Impact factor: 5.555

4.  Catalytic atroposelective synthesis of axially chiral benzonitriles via chirality control during bond dissociation and CN group formation.

Authors:  Ya Lv; Guoyong Luo; Qian Liu; Zhichao Jin; Xinglong Zhang; Yonggui Robin Chi
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

5.  The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions.

Authors:  Cecilie Melau; Malene Lundgaard Riis; John E Nielsen; Signe Perlman; Lene Lundvall; Lea Langhoff Thuesen; Kristine Juul Hare; Mette Schou Hammerum; Rod T Mitchell; Hanne Frederiksen; Anders Juul; Anne Jørgensen
Journal:  BMC Med       Date:  2021-09-08       Impact factor: 8.775

Review 6.  Hidden hypercortisolism: a too frequently neglected clinical condition.

Authors:  L Giovanelli; C Aresta; V Favero; M Bonomi; B Cangiano; C Eller-Vainicher; G Grassi; V Morelli; F Pugliese; A Falchetti; L Gennari; A Scillitani; L Persani; I Chiodini
Journal:  J Endocrinol Invest       Date:  2021-01-04       Impact factor: 4.256
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.